Medrano SJ, Domínguez GG, Sánchez MLC

Language: Spanish
References: 12
Page: 70-76
PDF size: 398.02 Kb.

ABSTRACT

Objetive: To know the clinical characteristics in Digital Rectal Examination (DRE) and Prostate Specific Antigen (PSA) value comparing with the pathology report in patients undergoing Transrectal Ultrasound prostate biopsy (TRUS biopsy). Material and methods: Study retrospective, observational, transverse, descriptive and open. Patients undergoing to TRUS biopsy in period study October 2003 to January 2006. Statistical evaluation was performed with descriptive statistical, Chi-Square test, Kruskall Wallis test. SPSS for Windows, version 12.0. Results: 340 patients were included. The mean age was 66.1 years. We take 3908 biopsies, a mean 10.4 biopsy/patient, the 92.6% of the biopsy cores were appropriate for pathology report. The 65.9% patients have a normal DRE. The pathology reports were: Benign (56.2%), Prostate Cancer (33.5%), PIN High Grade (8.2%) and Microgranular Atypia (2.1%). The mean value PSA was 17.67 ng/mL. We found a statistical difference between PSA value and pathology report (p ‹ 0.001). Patients with a normal DRE have a benign report in 73.3%, and prostate cancer in 51.8%. In the group of patients with a prostate cancer the 68% have PSA values lower than 20 ng/mL. The sensibility of PSA value was 68%. Conclusions: The PSA value and alteration in DRE can give us a probability percentage in the prediction of pathology report in a patient under TRUS biopsy.

REFERENCES

1. Jernal A, Tfwart RC, Murria T, et al. Cancer Statistics, 2004. CA Cancer J Clinic 2004; 54: 8-29.

2. Wals CP. Editor ultrasonography and biopsy of prostate: Campbell’s Urology. 8th Ed. Philadelphia: W.B. Saunders; 2002, p. 3038-44.

3. Van Der Cruijsen-Koeter IW, Wildhagen MF, De Koning HJ, Scrôder FH. The Value of current diagnostic testes in prostate cancer screening. BJU Int 2001; 88: 458- 66.

4. Argyropoulos A, Vassilakis G, Kalantzis A, Doumas K, Gkialas I, Lykourinas M. A novel 12-core biopsy scheme for the detection of prostate cancer by TRUS-biopsy of the prostate in patients with a total PSA from 4 to 20 ng/mL. BJU Int 2004; 94(Suppl. 2): 208.

5. Emilozzi P, Scarpone P, De Paula F, Pizzo M, Federico G, Pansadoro A, et al. The incidence of prostate cancer in men with prostate antigen greate than 4.0 ng/mL: a randomized study of 6 versus 12 core transperineal prostate biopsy. J Urol 2004; 171: 197-99.

6. Kiat T, Vasilareas D, Mitterdorfer A, Maher P, Lalak Andre. Prostate cancer detection with digital rectal examination prostate-specific antigen, transrectal ultrasonography and biopsy in clinical urological practice. BJU Int 2005; 95: 545-8.

7. Hodge KK, Mc Neal JE, Terris MK, Stamey TA. Random systematic versus directed ultrasound guided transrectal core biopsies of the prostate. J Urol 1989; 142 : 71.

8. Saadettin YE, Fuad G, Bulent A, Hasan SD, Ergen A, Ozen H. Individualizaton of the biopsy protocol according to the prostate gland volume for prostate cancer detection. J Urol 2005; 173: 1536-40.

9. Ciatto S, Vis A, Finne P. How to improve the specificity and sensivity of biopsy technique in screening. BJU Inter 2003; 92(Suppl. 2): 79-83.

10. 10.Young JM, Muscatello DJ, Ward JE. Are men with lower urinary tract symptoms at increased risk of prostate cancer? A systematic review and critique of the available evidence. BJU Inter 2000; 85(9): 1037-48.

11. 11.Cervera-Deval J, Morales-Olaya FJ, Jornet-Fayos J, González-Añon M. Valor diagnóstico de segundas biopsias prostáticas en varones de riesgo. Actas Urol Esp 2004; 28(9): 666-71.

12. 12.Herranz-Amo F, Diez-Cordero JM, Verdú-Tartajo F, Castaño- González I, Moraleja-Garate M, Martínez- Salamanca JI, et al. Evolución de las características clínicas, ecográficas y patológicas de los pacientes con indicación de ecografía transrectal y biopsia de próstata entre 1994 y 2003. Actas Urol Esp 2005; 29(1): 55- 63.